Hospital
Desert Regional Medical Center, INC.
Desert Regional Medical Center, INC. was paid $117.24M by Medicaid between Jan 2018 and Dec 2024, across 391 billing codes. Its largest line is 0450, Emergency room services — 26% of everything it billed.
33Billing provider infoDESERT REGIONAL MEDICAL CENTER, INC.
PALM SPRINGS, CA 92262
PALM SPRINGS, CA 92262
33aNPI1104856095assigned 07/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$117.24M
24GClaims1,669,470
24DCodes billed391
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#16 of 410
Median peer was paid$6.90M
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 229,020 | $13.01M | |
| 2019 | 256,066 | $15.73M | |
| 2020 | 185,485 | $13.21M | |
| 2021 | 223,918 | $15.05M | |
| 2022 | 243,620 | $18.49M | |
| 2023 | 274,104 | $20.81M | |
| 2024incomplete | 257,257 | $20.93M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 26% | 104,353 | 88,414 | $30.86M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 70,248 | 61,388 | $24.04M |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 8.4% | 950 | 659 | $9.90M |
| L8699 | Prosthetic implant, not otherwise specified | 6.5% | 1,398 | 1,343 | $7.59M |
| J2469 | Injection, palonosetron hcl, 25 mcg | 4.3% | 4,092 | 1,986 | $5.03M |
| Q5127 | Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | 2.6% | 295 | 202 | $3.03M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.5% | 1,142 | 1,116 | $1.71M |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 1.3% | 9,448 | 4,493 | $1.58M |
| Q5114 | Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg | 1.1% | 85 | 65 | $1.27M |
| J0690 | Injection, cefazolin sodium, 500 mg | 1.0% | 4,617 | 3,978 | $1.22M |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,600 | 8,530 | $1.13M |
| 0510 | <1% | 31,915 | 27,343 | $1.11M |
379 more codes
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 95 | $955K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,584 | $938K |
| J2704 | Injection, propofol, 10 mg | <1% | 7,127 | $914K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 196 | $802K |
| Z7502 | <1% | 19,555 | $735K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 205 | $709K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 20,494 | $612K |
| 99499 | <1% | 6,079 | $603K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 12,536 | $599K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,607 | $586K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,855 | $578K |
| J1201 | Injection, cetirizine hydrochloride, 0.5 mg | <1% | 638 | $547K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 16,822 | $477K |
| 0360 | <1% | 4,264 | $458K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 9,531 | $454K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 20,370 | $452K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 19,670 | $428K |
| J3490 | Unclassified drugs | <1% | 33,254 | $413K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,264 | $385K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,408 | $376K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,869 | $372K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 95,482 | $352K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,187 | $347K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12,089 | $332K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 26,932 | $331K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 4,051 | $330K |
| 99070 | <1% | 62,051 | $324K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 28,039 | $316K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,433 | $309K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 6,025 | $305K |
| 99221 | <1% | 1,905 | $304K | |
| 99285 | Emergency room visit (most serious) | <1% | 4,261 | $300K |
| 77066 | Tomosynthesis, mammo | <1% | 2,576 | $296K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,083 | $271K |
| J9306 | Injection, pertuzumab, 1 mg | <1% | 33 | $267K |
| 80053 | Comprehensive metabolic panel | <1% | 23,992 | $265K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 133 | $260K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,328 | $256K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,378 | $246K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 315 | $246K |
| 59025 | Fetal non-stress test | <1% | 12,426 | $246K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 5,006 | $237K |
| 97803 | <1% | 3,992 | $230K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,131 | $230K |
| 99284 | Emergency room visit (serious) | <1% | 4,224 | $229K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 6,786 | $225K |
| 97802 | <1% | 1,843 | $224K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 32,859 | $222K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 965 | $215K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 18,594 | $210K |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | <1% | 116 | $206K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,677 | $202K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 34,860 | $193K |
| Q3014 | Telehealth originating site facility fee | <1% | 7,515 | $179K |
| 0762 | <1% | 2,911 | $162K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 26,758 | $161K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 488 | $155K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,747 | $145K |
| 76642 | <1% | 2,482 | $143K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,399 | $136K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 30,557 | $130K |
| Z9725 | <1% | 3,999 | $128K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,041 | $116K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,714 | $112K |
| 96367 | <1% | 3,329 | $110K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 18,246 | $108K |
| 0750 | <1% | 677 | $106K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,710 | $105K |
| 80076 | <1% | 30,299 | $104K | |
| 0710 | <1% | 3,337 | $103K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,063 | $101K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,928 | $98K |
| 11043 | <1% | 3,204 | $97K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,038 | $97K |
| 72132 | <1% | 2,010 | $95K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,444 | $92K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,833 | $92K |
| 72129 | <1% | 1,946 | $92K | |
| 97750 | <1% | 2,090 | $88K | |
| 77065 | Tomosynthesis, mammo | <1% | 979 | $85K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14,639 | $84K |
| 82378 | <1% | 3,481 | $81K | |
| 82962 | <1% | 16,165 | $79K | |
| 96417 | <1% | 2,393 | $78K | |
| 71250 | <1% | 580 | $77K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 852 | $77K |
| 97139 | <1% | 3,171 | $77K | |
| 82728 | <1% | 5,256 | $76K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,178 | $73K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,176 | $73K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 7,495 | $71K |
| 83615 | <1% | 10,014 | $69K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,814 | $69K |
| 96415 | <1% | 2,265 | $67K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,074 | $64K |
| G0277 | Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval | <1% | 496 | $60K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,783 | $59K |
| 93017 | <1% | 1,677 | $58K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,619 | $57K |
| 71045 | Radiologic examination, chest; single view | <1% | 25,018 | $57K |
| 76830 | Ultrasound, transvaginal | <1% | 2,506 | $57K |
| H2000 | Comprehensive multidisciplinary evaluation | <1% | 813 | $54K |
| 0250 | <1% | 2,764 | $54K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,253 | $53K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,429 | $53K |
| 94060 | <1% | 1,315 | $52K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,664 | $52K |
| 80047 | <1% | 45,770 | $50K | |
| 11045 | <1% | 5,613 | $50K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,544 | $48K |
| 94729 | <1% | 1,169 | $48K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,301 | $48K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 899 | $47K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,400 | $46K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,918 | $46K |
| 82607 | <1% | 2,589 | $46K | |
| 90715 | <1% | 2,095 | $45K | |
| 83550 | <1% | 5,262 | $43K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 851 | $43K |
| G0378 | Hospital observation service, per hour | <1% | 2,177 | $43K |
| 73630 | <1% | 3,406 | $41K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,383 | $41K |
| 94726 | <1% | 1,108 | $40K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 966 | $40K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,049 | $39K |
| 82746 | <1% | 2,164 | $39K | |
| 83540 | <1% | 5,391 | $38K | |
| 73130 | <1% | 3,172 | $37K | |
| 93971 | <1% | 2,025 | $36K | |
| 87070 | <1% | 3,253 | $35K | |
| 86300 | <1% | 2,814 | $34K | |
| 88342 | <1% | 944 | $32K | |
| 76813 | <1% | 512 | $31K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 658 | $31K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 581 | $31K |
| 73610 | <1% | 2,952 | $31K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 500 | $30K |
| 84484 | <1% | 19,521 | $30K | |
| 87186 | <1% | 3,254 | $30K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,682 | $29K |
| 76801 | <1% | 3,329 | $28K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 174 | $27K |
| 70486 | <1% | 752 | $27K | |
| 88304 | <1% | 2,028 | $26K | |
| 77336 | <1% | 616 | $25K | |
| 81001 | <1% | 29,696 | $25K | |
| 85730 | <1% | 7,655 | $24K | |
| Z7610 | <1% | 1,824 | $24K | |
| 99218 | <1% | 165 | $24K | |
| 73030 | <1% | 2,937 | $24K | |
| 0272 | <1% | 1,846 | $24K | |
| Z7500 | <1% | 689 | $23K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 6,865 | $23K |
| 74246 | <1% | 379 | $23K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,776 | $23K |
| 97799 | <1% | 1,286 | $22K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 871 | $21K |
| 85610 | <1% | 9,596 | $21K | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 597 | $21K |
| 83690 | <1% | 22,589 | $20K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,399 | $20K |
| 73100 | <1% | 1,332 | $20K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 54 | $19K |
| 73564 | <1% | 1,639 | $19K | |
| 83735 | <1% | 5,276 | $19K | |
| 88313 | <1% | 974 | $19K | |
| 95819 | <1% | 419 | $19K | |
| 86850 | <1% | 5,209 | $18K | |
| 70498 | <1% | 472 | $18K | |
| 82375 | <1% | 1,005 | $18K | |
| 84703 | <1% | 2,865 | $18K | |
| 97763 | <1% | 522 | $18K | |
| 81025 | <1% | 25,348 | $18K | |
| 93312 | <1% | 160 | $17K | |
| 74178 | <1% | 132 | $17K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 308 | $17K |
| 93923 | <1% | 205 | $17K | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 139 | $17K |
| 29581 | <1% | 694 | $17K | |
| 87077 | <1% | 3,255 | $16K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 260 | $16K |
| 0681 | <1% | 25 | $16K | |
| 96368 | <1% | 1,150 | $15K | |
| 73110 | <1% | 1,461 | $14K | |
| 73562 | <1% | 2,008 | $14K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 222 | $14K |
| 84439 | <1% | 1,853 | $14K | |
| 72131 | <1% | 571 | $14K | |
| S9452 | Nutrition classes, non-physician provider, per session | <1% | 129 | $13K |
| A4217 | Sterile water/saline, 500 ml | <1% | 1,780 | $13K |
| 73590 | <1% | 1,633 | $13K | |
| 71270 | <1% | 68 | $13K | |
| 77080 | <1% | 472 | $13K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 393 | $12K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 57 | $12K |
| 88307 | <1% | 366 | $12K | |
| 74240 | <1% | 192 | $11K | |
| 20610 | <1% | 589 | $11K | |
| 81003 | <1% | 23,173 | $11K | |
| 11046 | <1% | 951 | $11K | |
| 96376 | <1% | 1,150 | $11K | |
| 84702 | <1% | 6,979 | $11K | |
| 86901 | <1% | 7,259 | $11K | |
| 0270 | <1% | 1,952 | $11K | |
| 83605 | <1% | 6,492 | $11K | |
| 72170 | <1% | 2,134 | $10K | |
| 72100 | <1% | 673 | $10K | |
| 12001 | <1% | 1,318 | $10K | |
| 73502 | <1% | 958 | $10K | |
| 73090 | <1% | 1,301 | $10K | |
| 80306 | <1% | 3,591 | $10K | |
| 77412 | <1% | 143 | $10K | |
| 96411 | <1% | 388 | $10K | |
| 10060 | <1% | 881 | $9K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 92 | $9K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,361 | $9K |
| 86900 | <1% | 7,266 | $8K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 426 | $8K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 367 | $8K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,898 | $8K |
| 86923 | <1% | 111 | $7K | |
| 87040 | <1% | 2,355 | $7K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 137 | $7K |
| 96402 | <1% | 690 | $7K | |
| 73552 | <1% | 664 | $7K | |
| 76870 | <1% | 561 | $7K | |
| 12011 | <1% | 655 | $6K | |
| 29125 | <1% | 1,090 | $6K | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 151 | $6K |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 101 | $6K |
| 99199 | Unlisted special service, procedure or report | <1% | 125 | $6K |
| 94664 | <1% | 4,981 | $6K | |
| 87081 | <1% | 1,372 | $6K | |
| 96152 | <1% | 108 | $6K | |
| 80143 | <1% | 2,101 | $6K | |
| 70496 | <1% | 135 | $5K | |
| 72110 | <1% | 267 | $5K | |
| 83880 | <1% | 1,534 | $5K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 313 | $5K |
| 72128 | <1% | 153 | $5K | |
| 88341 | <1% | 33 | $5K | |
| 74018 | <1% | 1,536 | $5K | |
| 77062 | <1% | 59 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 689 | $5K |
| 72040 | <1% | 304 | $4K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $4K |
| 93970 | <1% | 96 | $4K | |
| 84153 | <1% | 258 | $4K | |
| 77300 | <1% | 13 | $4K | |
| 80179 | <1% | 2,098 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,403 | $4K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,085 | $4K |
| 12002 | <1% | 571 | $4K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 136 | $4K |
| 99217 | <1% | 138 | $4K | |
| 73070 | <1% | 278 | $4K | |
| 76536 | <1% | 78 | $4K | |
| 73080 | <1% | 705 | $4K | |
| 97597 | <1% | 128 | $4K | |
| 85379 | <1% | 2,121 | $4K | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 282 | $4K |
| 0002A | <1% | 89 | $4K | |
| 84100 | <1% | 1,500 | $3K | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 108 | $3K |
| 70491 | <1% | 79 | $3K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 434 | $3K |
| 82248 | <1% | 604 | $3K | |
| 85018 | <1% | 1,149 | $3K | |
| 0761 | <1% | 91 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,226 | $3K |
| 80061 | Lipid panel | <1% | 1,024 | $3K |
| 76641 | <1% | 27 | $3K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 62 | $3K |
| 77290 | <1% | 27 | $3K | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 56 | $2K |
| A9270 | Non-covered item or service | <1% | 3,426 | $2K |
| 0001A | <1% | 61 | $2K | |
| 73120 | <1% | 324 | $2K | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 84 | $2K |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 66 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 70 | $2K |
| 73060 | <1% | 257 | $2K | |
| Z7506 | <1% | 15 | $2K | |
| 29515 | <1% | 193 | $2K | |
| 0271 | <1% | 42 | $2K | |
| 73620 | <1% | 375 | $2K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 31 | $2K |
| 99402 | <1% | 25 | $2K | |
| 82077 | <1% | 758 | $2K | |
| 86304 | <1% | 146 | $2K | |
| 82550 | <1% | 1,649 | $2K | |
| 47562 | <1% | 12 | $2K | |
| 97161 | <1% | 107 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 38 | $2K |
| 73560 | <1% | 152 | $2K | |
| 0012A | <1% | 42 | $2K | |
| 88302 | <1% | 129 | $2K | |
| 29075 | <1% | 267 | $2K | |
| 96416 | <1% | 39 | $2K | |
| 49083 | <1% | 27 | $2K | |
| 85027 | <1% | 792 | $2K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 16 | $1K |
| A9150 | Non-prescription drugs | <1% | 346 | $1K |
| 82150 | <1% | 733 | $1K | |
| 76770 | <1% | 37 | $1K | |
| 84550 | <1% | 752 | $1K | |
| 97165 | <1% | 44 | $1K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 14 | $1K |
| 87147 | <1% | 321 | $1K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 23 | $1K |
| 86140 | <1% | 875 | $1K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 32 | $1K |
| 99224 | <1% | 17 | $1K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 46 | $903.94 |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 59 | $895.94 |
| 88300 | <1% | 204 | $851.11 | |
| 84145 | <1% | 333 | $832.62 | |
| 87075 | <1% | 62 | $785.49 | |
| 87593 | <1% | 14 | $772.00 | |
| 73600 | <1% | 80 | $658.80 | |
| 82105 | <1% | 54 | $604.02 | |
| 0011A | <1% | 15 | $600.01 | |
| 73140 | <1% | 68 | $595.95 | |
| 82570 | <1% | 497 | $586.35 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 47 | $582.99 |
| J1815 | Injection, insulin, per 5 units | <1% | 444 | $541.98 |
| 82784 | <1% | 84 | $533.49 | |
| 76820 | <1% | 17 | $531.70 | |
| 85651 | <1% | 500 | $526.43 | |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 84 | $519.30 |
| 71020 | <1% | 122 | $514.27 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 269 | $509.83 |
| 71010 | <1% | 223 | $483.45 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 103 | $470.72 |
| 82731 | <1% | 364 | $465.52 | |
| 99195 | <1% | 31 | $443.44 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 14 | $439.59 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 14 | $438.87 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 31 | $430.67 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 25 | $391.97 |
| Z7512 | <1% | 15 | $391.95 | |
| 73700 | <1% | 14 | $382.16 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 57 | $369.80 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 309 | $369.49 |
| 87430 | <1% | 405 | $326.49 | |
| 86703 | <1% | 73 | $236.94 | |
| 29065 | <1% | 35 | $224.40 | |
| 72070 | <1% | 15 | $224.14 | |
| 82805 | <1% | 13 | $193.00 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 625 | $192.64 |
| 73000 | <1% | 15 | $191.82 | |
| 84156 | <1% | 416 | $187.19 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,311 | $177.48 |
| 90686 | <1% | 12 | $168.72 | |
| 87210 | <1% | 426 | $127.85 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 15 | $118.42 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 353 | $104.43 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $99.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $99.00 |
| 29130 | <1% | 26 | $97.41 | |
| 87420 | <1% | 185 | $96.33 | |
| 82565 | <1% | 126 | $93.44 | |
| 84403 | <1% | 41 | $88.02 | |
| 87205 | <1% | 15 | $70.37 | |
| 84402 | <1% | 29 | $68.46 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 69 | $49.61 |
| 20550 | <1% | 16 | $41.35 | |
| 74022 | <1% | 12 | $36.75 | |
| 51702 | <1% | 19 | $33.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 17 | $32.56 |
| 74000 | <1% | 33 | $32.28 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 23 | $29.03 |
| 86592 | <1% | 14 | $22.82 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 124 | $14.67 |
| 84460 | <1% | 51 | $7.67 | |
| 84450 | <1% | 51 | $7.67 | |
| 85007 | <1% | 15 | $4.80 | |
| 84112 | 0% | 254 | $0.00 | |
| 96377 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFISH, JIMMY (CFO)
| Provider | Location | Paid |
|---|---|---|
| JFK Memorial Hospital, INC. | Indio, CA | $61.66M |
| HDMC Holdings, LLC | Joshua Tree, CA | $10.71M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.